Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2008

View Archived Issues

Hsp90 inhibitors demonstrate antitumor effects in preclinical studies

Novel inhibitor of tyrosine kinases shows antitumor activity in preclinical models

MI-219 displays preclinical anticancer activity

AEterna Zentaris develops new cytotoxic conjugate, AEZS-125

FDA approves Calando's IND application for siRNA nanoparticle therapeutic CALAA-01

Cosmo reports positive results from phase IIb trial of Heparin MMX for ulcerative colitis

Actelion and Nippon Shinyaku sign license agreement for NS-304 for PAH

Genentech reports additional positive results from phase III AVAil clinical study of Avastin

Starpharma reports results from studies of VivaGel in genital warts and cervical cancer

Dainippon Sumitomo Pharma launches Lonasen for schizophrenia

Q1 highlights at Gilead Sciences

InterMune to initiate open-label rollover study of pirfenidone in IPF in August 2008

BioAlliance Pharma and Strativa announce phase III study results for Loramyc in OPC

New treatment options for obesity and lipoprotein disorders reported in recent patents

Optimer Pharmaceuticals reveals preliminary data on safety and pharmacokinetics for OPT-80

Angiotech suspends enrollment in U.S. and E.U. human clinical trials for Vascular Wrap

ErepoXen shows positive results from phase I trial

Recent AstraZeneca patent discloses new treatment options for gastrointestinal disorders

Novel agents for neurological disorders described in recent AstraZeneca and Merck Frosst patents

Almirall presents promising results for new asthma and COPD compound

Combination of dutasteride with tamsulosin approved for the treatment of BPH

Inspire discontinues epinastine nasal spray development

Replidyne discontinues phase III faropenem trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...